1Mc Caughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Asso- ciation for the liver consenesus statements on the diagnosis, management and treatment of hepatitis C virus infection [J]. J Gastroenterol Hepatol, 2007,22(5):615-633. 被引量：1
4Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update [J]. Hepatology,2009,49(4):1335- 1374. 被引量：1
5徐道振编著..病毒性肝炎临床实践[M].北京:人民卫生出版社,2006:677.
二级参考文献22
1Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009,49(4): 1335-1374. 被引量：1
2McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection[J]. J Gastroenterol Hepatol,2007,22(5): 615-633. 被引量：1
3Gordon SC. Treatment of viral hepatitis-2001 [J]. Ann Med, 2001,33(6):385-390. 被引量：1
4Pawlotsky JM. Treating hepatitis C in "difficult-to-treat" patients[J]. N Engl J Med, 2004,351 (5):422-423. 被引量：1
5Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin[J]. Hepatology,2008,48(4): 1033-1043. 被引量：1
6Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? [J]. Liver Int,2009,29(Suppl 1):S15-S18. 被引量：1
7Farnik H, Mihm U ,Zeuzem S. Optimal therapy in genotype 1 patients[J]. Liver Int, 2009,29(Suppl 1):S23-S30. 被引量：1
8Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy[J]. Gastroenterology, 2009, 136(5):1618-1628. 被引量：1
9Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha 2b: a randomized trial[J]. Ann Intern Med, 2009,150(8):528-540. 被引量：1
10McHutchison JG, Shiffman ML, Terrault N, et al. A phase 2b study of telaprevir with peginterferon-alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alfa- 2a/b and ribavirin therapy: PROVE3 interim resuhs[C/OL]// 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, October 31- November 1, 2008. [2009-06-10]. http://www.natap.org/2008/ AASLD/AASLD_14.htm. 被引量：1
5El Khayat HR, Fouad YM, E1 Amin H, et al. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus fibavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. Trop Gastroentero1,2012,33 ( 2 ) : 112-117. 被引量：1
6Gentil Govantes MA, Esforzado N, Cruzado JM, et al. Harmful effects of viral replication in seropositive hepatitis C virus renal transplant recipients. Transplantation,2012,94 ( 11 ) : 1131-1137. 被引量：1
7Shaikh S, Devrajani BR, Kalhoro M. Efficacy of PEG-interferon based treatment in patients with hepatitis C refractory to previous conventional interferon-based treatment. J Coil Physicians Surg Pak,2012,22(10) :635-639. 被引量：1
8Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of in- jectable extended-release nahrexone in patients with chronic hep- atitis C and HIV infection. J Stud Alcohol Drugs, 2012,73 (6): 991-997. 被引量：1
9Lalezari J, Asmuth D, Casir6 A, et al. Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. Antimicrob A- gents Chemother,2012,56(12) :6372-6378. 被引量：1
10Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients [ J]. J Acquir Immune Defie Syndr,2006,41 ( 1 ) :31 - 36. 被引量：1
